GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges : Episode 6
Integration of GPRC5D-Targeted Therapies in RRMM Treatment
Panelists discuss how GPRC5D-targeted bispecifics are likely to be incorporated earlier in treatment sequencing for multiple myeloma in the future, while considering factors such as optimal timing, potential combinations with other therapies, sequencing strategies, and possible drug interactions when integrating these treatments into the overall management of relapsed/refractory multiple myeloma patients.
- Where in treatment sequencing do you foresee future GPRC5D-targeted bispecifcs being incorporated?
- How have you integrated GPRC5D-targeted therapies into the overall treatment landscape for heavily pre-treated RRMM patients?
- What considerations should be made when integrating GPRC5D-targeted treatments alongside other therapies in terms of sequencing, combination approaches, and potential drug-drug interactions
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
